The United States’ Food and Drug Administration (FDA) has approved the use of PD-1 and PD-L1 inhibitors as the second-line treatment of metastatic or locally advanced bladder cancer and for the first-line management of PD-L1-positive patients who are ineligible for platinum-based chemotherapy [18,38]. Here, CD274 is linked to urinary bladder cancer.